Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 6:45 PM
Ignite Modification Date: 2025-12-25 @ 4:16 PM
NCT ID: NCT02213757
Description: None
Frequency Threshold: 0
Time Frame: None
Study: NCT02213757
Study Brief: Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Premarin Vaginal Cream Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks. Premarin vaginal estrogen cream None None 0 15 0 15 View
Placebo Vaginal Cream Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks. Placebo vaginal cream: Inactive vaginal cream manufactured to mimic Premarin vaginal cream None None 0 14 0 14 View
Serious Events(If Any):
Other Events(If Any):